Login
$NGNE
$23.30 +$0.00 (0.0%) After hours

$NGNE SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

EVERY BREAKTHROUGH BEGINS WITH BELIEF November 2026 Corporate Presentation

07 Oct 2026 SCHEDULE 13G
06 Oct 2026 SCHEDULE 13G
02 Oct 2026 Form 4: McMinn Rachel, Director

Received 756 shares by exercise or conversion ($19.1K)

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

EVERY BREAKTHROUGH BEGINS WITH BELIEF August 2026 Corporate Presentation

07 Jul 2026 Form 4: Cvijic Christine Mikail, Director

Sold 600 shares ($21.6K) · Sold 4,200 shares ($152K)

02 Jul 2026 Form 4: Cvijic Christine Mikail, Director

Sold 739 shares ($25.2K) · Sold 4,061 shares ($141K)

02 Jul 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Pre-Funded Warrants to purchase up to 666,666 shares of Common Stock

02 Jul 2026 424B5
30 Jun 2026 424B5
29 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Restarting Development in Rett Syndrome NGN-401 for Rett Syndrome Phase 1/2 Update June 29, 2026

16 Jun 2026 Form 4/A: Woods Keith, Director

Granted 15,400 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support